These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 11061497

  • 1. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.
    Greenspan SL, Rosen HN, Parker RA.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3537-40. PubMed ID: 11061497
    [Abstract] [Full Text] [Related]

  • 2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 3. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL, Resnick NM, Parker RA.
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [Abstract] [Full Text] [Related]

  • 4. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC.
    Osteoporos Int; 2000 May; 11(4):295-303. PubMed ID: 10928218
    [Abstract] [Full Text] [Related]

  • 5. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D.
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [Abstract] [Full Text] [Related]

  • 6. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 7. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 8. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

  • 9. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
    [Abstract] [Full Text] [Related]

  • 11. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
    Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S.
    Calcif Tissue Int; 1998 Aug; 63(2):102-6. PubMed ID: 9685512
    [Abstract] [Full Text] [Related]

  • 12. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD.
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [Abstract] [Full Text] [Related]

  • 13. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 14. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD.
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [Abstract] [Full Text] [Related]

  • 15. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 16. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Jul; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 17. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group.
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 20. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.